The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females

Dimpi Patel, Prasant Mohanty, Luigi Di Biase, Yan Wang, Mazen H. Shaheen, Javier E. Sanchez, Rodney P. Horton, G. Joseph Gallinghouse, Jason D. Zagrodzky, Shane M. Bailey, J. David Burkhardt, William R. Lewis, Alberto Diaz, Salwa Beheiry, Richard Hongo, Amin Al-Ahmad, Paul Wang, Robert Schweikert, Andrea Natale

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Aims To assess whether treatment with statins or renin-angiotensin- aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS). Methods and results Five hundred and eighteen consecutive female patients had undergone AF catheter ablation from January 2005 to May 2008. Post-menopausal females were selected and procedure outcomes were compared between cohorts of PMFS treated with statins or RAAS inhibitors to untreated PMFS. Out of 408 PMFS, 36 (8.8) were treated with a combination of RAAS inhibitors and statins, thus were excluded leaving a total of 372 (91.2) patients in the study. Out of 372 patients, 111 (29.8) were on statins (Group 1), 59 (15.9) on RAAS inhibitors (Group 2), and 202 (54.3) without RAAS inhibitors or statins [(Group 3) control population]. Over a mean follow-up time of 24 ± 8.3 (median 25) months, 78 (70.6) in Group 1, 38 (65.4) in Group 2, and 139 (68.8) in Group 3 had procedural success. Statin or RAAS inhibitor use did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in the cumulative incidence of recurrence was found with statin or RAAS inhibitors use (P = 0.385 and P = 0.761, respectively). Conclusion Treatment with statins or RAAS inhibitors did not improve catheter ablation success rates among PMFS. Thereby, from a clinical standpoint, PMFS should not be started on these treatments as a procedural 'augmenting agent' at this time.

Original languageEnglish (US)
Pages (from-to)322-330
Number of pages9
JournalEuropace
Volume12
Issue number3
DOIs
StatePublished - Mar 2010
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pulmonary Veins
Renin-Angiotensin System
Catheter Ablation
Recurrence
Atrial Fibrillation
Therapeutics
Control Groups
Incidence

Keywords

  • Atrial fibrillation
  • Post-menopausal female
  • Pulmonary vein antrum isolation
  • Renin-angiotensin-aldosterone system blockers
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females. / Patel, Dimpi; Mohanty, Prasant; Di Biase, Luigi; Wang, Yan; Shaheen, Mazen H.; Sanchez, Javier E.; Horton, Rodney P.; Gallinghouse, G. Joseph; Zagrodzky, Jason D.; Bailey, Shane M.; Burkhardt, J. David; Lewis, William R.; Diaz, Alberto; Beheiry, Salwa; Hongo, Richard; Al-Ahmad, Amin; Wang, Paul; Schweikert, Robert; Natale, Andrea.

In: Europace, Vol. 12, No. 3, 03.2010, p. 322-330.

Research output: Contribution to journalArticle

Patel, D, Mohanty, P, Di Biase, L, Wang, Y, Shaheen, MH, Sanchez, JE, Horton, RP, Gallinghouse, GJ, Zagrodzky, JD, Bailey, SM, Burkhardt, JD, Lewis, WR, Diaz, A, Beheiry, S, Hongo, R, Al-Ahmad, A, Wang, P, Schweikert, R & Natale, A 2010, 'The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females', Europace, vol. 12, no. 3, pp. 322-330. https://doi.org/10.1093/europace/eup387
Patel, Dimpi ; Mohanty, Prasant ; Di Biase, Luigi ; Wang, Yan ; Shaheen, Mazen H. ; Sanchez, Javier E. ; Horton, Rodney P. ; Gallinghouse, G. Joseph ; Zagrodzky, Jason D. ; Bailey, Shane M. ; Burkhardt, J. David ; Lewis, William R. ; Diaz, Alberto ; Beheiry, Salwa ; Hongo, Richard ; Al-Ahmad, Amin ; Wang, Paul ; Schweikert, Robert ; Natale, Andrea. / The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females. In: Europace. 2010 ; Vol. 12, No. 3. pp. 322-330.
@article{5bfb20f0d918463b96184d249be939c1,
title = "The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females",
abstract = "Aims To assess whether treatment with statins or renin-angiotensin- aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS). Methods and results Five hundred and eighteen consecutive female patients had undergone AF catheter ablation from January 2005 to May 2008. Post-menopausal females were selected and procedure outcomes were compared between cohorts of PMFS treated with statins or RAAS inhibitors to untreated PMFS. Out of 408 PMFS, 36 (8.8) were treated with a combination of RAAS inhibitors and statins, thus were excluded leaving a total of 372 (91.2) patients in the study. Out of 372 patients, 111 (29.8) were on statins (Group 1), 59 (15.9) on RAAS inhibitors (Group 2), and 202 (54.3) without RAAS inhibitors or statins [(Group 3) control population]. Over a mean follow-up time of 24 ± 8.3 (median 25) months, 78 (70.6) in Group 1, 38 (65.4) in Group 2, and 139 (68.8) in Group 3 had procedural success. Statin or RAAS inhibitor use did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in the cumulative incidence of recurrence was found with statin or RAAS inhibitors use (P = 0.385 and P = 0.761, respectively). Conclusion Treatment with statins or RAAS inhibitors did not improve catheter ablation success rates among PMFS. Thereby, from a clinical standpoint, PMFS should not be started on these treatments as a procedural 'augmenting agent' at this time.",
keywords = "Atrial fibrillation, Post-menopausal female, Pulmonary vein antrum isolation, Renin-angiotensin-aldosterone system blockers, Statins",
author = "Dimpi Patel and Prasant Mohanty and {Di Biase}, Luigi and Yan Wang and Shaheen, {Mazen H.} and Sanchez, {Javier E.} and Horton, {Rodney P.} and Gallinghouse, {G. Joseph} and Zagrodzky, {Jason D.} and Bailey, {Shane M.} and Burkhardt, {J. David} and Lewis, {William R.} and Alberto Diaz and Salwa Beheiry and Richard Hongo and Amin Al-Ahmad and Paul Wang and Robert Schweikert and Andrea Natale",
year = "2010",
month = "3",
doi = "10.1093/europace/eup387",
language = "English (US)",
volume = "12",
pages = "322--330",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females

AU - Patel, Dimpi

AU - Mohanty, Prasant

AU - Di Biase, Luigi

AU - Wang, Yan

AU - Shaheen, Mazen H.

AU - Sanchez, Javier E.

AU - Horton, Rodney P.

AU - Gallinghouse, G. Joseph

AU - Zagrodzky, Jason D.

AU - Bailey, Shane M.

AU - Burkhardt, J. David

AU - Lewis, William R.

AU - Diaz, Alberto

AU - Beheiry, Salwa

AU - Hongo, Richard

AU - Al-Ahmad, Amin

AU - Wang, Paul

AU - Schweikert, Robert

AU - Natale, Andrea

PY - 2010/3

Y1 - 2010/3

N2 - Aims To assess whether treatment with statins or renin-angiotensin- aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS). Methods and results Five hundred and eighteen consecutive female patients had undergone AF catheter ablation from January 2005 to May 2008. Post-menopausal females were selected and procedure outcomes were compared between cohorts of PMFS treated with statins or RAAS inhibitors to untreated PMFS. Out of 408 PMFS, 36 (8.8) were treated with a combination of RAAS inhibitors and statins, thus were excluded leaving a total of 372 (91.2) patients in the study. Out of 372 patients, 111 (29.8) were on statins (Group 1), 59 (15.9) on RAAS inhibitors (Group 2), and 202 (54.3) without RAAS inhibitors or statins [(Group 3) control population]. Over a mean follow-up time of 24 ± 8.3 (median 25) months, 78 (70.6) in Group 1, 38 (65.4) in Group 2, and 139 (68.8) in Group 3 had procedural success. Statin or RAAS inhibitor use did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in the cumulative incidence of recurrence was found with statin or RAAS inhibitors use (P = 0.385 and P = 0.761, respectively). Conclusion Treatment with statins or RAAS inhibitors did not improve catheter ablation success rates among PMFS. Thereby, from a clinical standpoint, PMFS should not be started on these treatments as a procedural 'augmenting agent' at this time.

AB - Aims To assess whether treatment with statins or renin-angiotensin- aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS). Methods and results Five hundred and eighteen consecutive female patients had undergone AF catheter ablation from January 2005 to May 2008. Post-menopausal females were selected and procedure outcomes were compared between cohorts of PMFS treated with statins or RAAS inhibitors to untreated PMFS. Out of 408 PMFS, 36 (8.8) were treated with a combination of RAAS inhibitors and statins, thus were excluded leaving a total of 372 (91.2) patients in the study. Out of 372 patients, 111 (29.8) were on statins (Group 1), 59 (15.9) on RAAS inhibitors (Group 2), and 202 (54.3) without RAAS inhibitors or statins [(Group 3) control population]. Over a mean follow-up time of 24 ± 8.3 (median 25) months, 78 (70.6) in Group 1, 38 (65.4) in Group 2, and 139 (68.8) in Group 3 had procedural success. Statin or RAAS inhibitor use did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in the cumulative incidence of recurrence was found with statin or RAAS inhibitors use (P = 0.385 and P = 0.761, respectively). Conclusion Treatment with statins or RAAS inhibitors did not improve catheter ablation success rates among PMFS. Thereby, from a clinical standpoint, PMFS should not be started on these treatments as a procedural 'augmenting agent' at this time.

KW - Atrial fibrillation

KW - Post-menopausal female

KW - Pulmonary vein antrum isolation

KW - Renin-angiotensin-aldosterone system blockers

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=77749324818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749324818&partnerID=8YFLogxK

U2 - 10.1093/europace/eup387

DO - 10.1093/europace/eup387

M3 - Article

C2 - 20064822

AN - SCOPUS:77749324818

VL - 12

SP - 322

EP - 330

JO - Europace

JF - Europace

SN - 1099-5129

IS - 3

ER -